Pentair Plc logo

Pentair Plc(STG) PNT

Market Cap$7.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+40%
5 YearN/A
1 Year+75%
1 Month-8%
$49.26
-0.12%
-0.06Today
Pentair Plc last closing stock price
MetricPriceDate
Last closeEUR 12.502023-12-29
Pentair Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.16%EUR 12.482023-12-22
1 month-8.42%EUR 13.652023-11-29
3 month+87.41%EUR 6.672023-09-29
Year to date+71.47%EUR 7.292022-12-30
1 year+75.07%EUR 7.142022-12-29
3 year-9.78%EUR 13.862020-12-29
Since inception+39.62%EUR 35.322019-04-08

Pentair Plc Financials at a Glance

Market Cap

$7.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$243.69M

Net Income (TTM)

$96.55M

EPS (TTM)

$3.41

P/E Ratio

14.48

Dividend

$1.15

Beta (Volatility)

0.00 (Low)

Price

$49.26

Volume

22

Open

$49.17

Previous Close

$49.26

Daily Range

$49.13 - $49.77

52-Week Range

$45.63 - $94.74

Estimated Earnings Date

Mar 22, 2024

PNT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pentair Plc

POINT Biopharma Global Inc. is a radiopharmaceutical company focused on developing and commercializing innovative radioligand therapies for various cancer types. The company is advancing two primary investigational treatments, PNT2002 and PNT2003, both currently in Phase III clinical trials.

Products and Services
  • PNT2002 targets prostate-specific membrane antigen for metastatic castration-resistant prostate cancer
  • PNT2003 is a somatostatin-targeted radioligand for neuroendocrine tumors
  • Pipeline includes PNT2001 and PNT-2004, targeting various tumor types
Growth Outlook
  • Strong pipeline with two Phase III trials expected to drive future growth
  • Potential market expansion through innovative CanSEEK technology
  • Increasing demand for targeted cancer therapies supports long-term growth
Financial Highlights
  • Q3 2023 revenue of $2.79 million, showing resilience in a challenging market
  • Cash and short-term investments totaled $339.16 million as of Q3 2023
  • Operating expenses for Q3 2023 were $32.42 million, reflecting ongoing R&D investments
POINT Biopharma Global Inc. operates in the biotechnology sector, focusing on innovative cancer treatments. The company has made significant strides in its clinical programs, with two key therapies in late-stage trials. The financial position remains robust, with substantial cash reserves that provide a buffer for ongoing research and development efforts. The recent quarterly results indicate a commitment to advancing its pipeline, despite the inherent challenges in the biotechnology industry. Investors may find POINT Biopharma's focus on targeted therapies and its strong financial foundation appealing as the company navigates the complexities of drug development and commercialization.
AI Generated • Oct 3, 2026

Industry

Machinery

Employees

9,000

CEO

John L. Stauch

Headquarters

Indianapolis, IN 46268, US

PNT Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

55.40%

Net Income Margin

43.38%

Return on Equity

26.49%

Return on Capital

25.78%

Return on Assets

17.00%

Earnings Yield

6.91%

Dividend Yield

2.34%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

159.64M

Volume

22

Avg. Volume

104.894

Financials (TTM)

Gross Profit

$9.69B

Operating Income

$107.77M

EBITDA

-$6.06B

Operating Cash Flow

$112.06M

Capital Expenditure

-$19.32M

Free Cash Flow

$92.74M

Cash & ST Invst.

$339.16M

Total Debt

$10.66M

Pentair Plc Performance Analysis

Pentair Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,921,884,61223.1%
20232023-12-31USD 3,796,541,266-3.2%
20242024-12-31USD 3,774,461,394-0.6%
20252025-12-31USD 3,700,231,781-2.0%
Pentair Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31-95.8%
Q22023-06-30-48.5%
Q32023-09-30-42.7%
Pentair Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.76-1.1%
20232023-12-31USD 3.4625.3%
20242024-12-31USD 3.46-0.1%
20252025-12-31USD 3.501.2%
Pentair Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31753.8%
Q12023-03-31-109.4%
Q22023-06-30-50.0%
Q32023-09-304.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$2.79M

N/A

Gross Profit

$2.79M

N/A

Gross Margin

100.00%

N/A

Market Cap

$7.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$61.03M

N/A

Employees

129

N/A

Net Income

-$24.77M

-3.2%

EBITDA

-$34.49M

-54.0%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$339.16M

+16.3%

Total Debt

$10.66M

N/A

Accounts Receivable

$9.39M

+5434.9%

Inventory

$4.20M

N/A

Long Term Debt

$8.74M

N/A

Short Term Debt

$1.93M

N/A

Return on Assets

17.00%

N/A

Return on Invested Capital

25.18%

N/A

Free Cash Flow

-$34.53M

-15.3%

Operating Cash Flow

-$28.13M

-26.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CINCCinCor Pharma, Inc.
$29.06+0.00%
CTICCTI BioPharma Corp.
$9.10+0.06%
EQRXEQRx, Inc.
$2.34-2.09%
VECTVectivBio Holding AG
$16.87+0.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About PNT

What is the current price of Pentair Plc?

Pentair Plc is trading at $49.26 per share.

What is the 52-week range for Pentair Plc?

Over the past 52 weeks, Pentair Plc has traded between $45.63 and $94.74.

How much debt does Pentair Plc have?

As of the most recent reporting period, Pentair Plc reported total debt of $1.54B.

How much cash does Pentair Plc have on hand?

Pentair Plc reported $80.29M in cash and cash equivalents in its most recent financial results.

What is Pentair Plc’s dividend yield?

Pentair Plc currently has a dividend yield of 2.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.